Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial.

Nature medicine·2026

Same author

A reassessment of anti-CAR T-cell expansion strategies.

Blood·2026

Same author

Adoptive T-Cell Immunotherapy.

Current topics in microbiology and immunology·2026

Same author

Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT.

Transplantation and cellular therapy·2026

Same author

Treatment of extracranial rhabdoid tumor with intensive ifosfamide-containing chemotherapy regimens.

Frontiers in oncology·2026

Same author

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.

Proceedings of the National Academy of Sciences of the United States of America·2026

Search research articles

Related Experiment Video

Updated: May 28, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Adoptive Cell Therapy for Pediatric Solid Tumors.

Amy B Hont¹, Catherine M Bollard²

¹Center for Cancer and Immunology Research, Children's National Hospital, Washington, D.C. 20010, USA.

Cold Spring Harbor Perspectives in Medicine

|February 10, 2025

Summary

Adoptive cell therapy (ACT) offers a promising new avenue for treating relapsed or refractory pediatric solid tumors, addressing a critical unmet need. This review explores ACT development, challenges, and clinical outcomes for improved pediatric cancer immunotherapy.

More Related Videos

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

Related Experiment Videos

Last Updated: May 28, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

Area of Science:

Oncology
Immunotherapy
Pediatric Medicine

Background:

Relapsed or refractory pediatric solid tumors have limited treatment options with poor outcomes.
Adoptive cell therapy (ACT) presents a targeted approach with potential for reduced toxicity.

Purpose of the Study:

To review the development and manufacturing of ACT for pediatric solid tumors.
To discuss challenges in targeting and treating solid tumors with ACT.
To evaluate clinical outcomes, future potential, and novel strategies in pediatric ACT.

Main Methods:

Comprehensive literature review of clinical trials and studies on ACT for pediatric solid tumors.
Analysis of ACT product development, manufacturing processes, and clinical application data.
Examination of obstacles and successes in applying ACT to solid tumors.

Main Results:

ACT approaches are being developed and manufactured for pediatric solid tumors.
Significant obstacles exist in targeting and treating solid tumors effectively with ACT.
Clinical outcomes of various ACT products show promise but require further investigation.

Conclusions:

ACT is a developing immunotherapy with potential for pediatric solid tumors.
Addressing challenges in ACT development and application is crucial for clinical success.
Future directions include novel product development and combination therapies for enhanced efficacy.